AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-13 (cancelled)

14. (currently amended) A method of evaluating binding affinity of a test compound to alpha platelet derived growth factor receptor (α PDGFR) ~~or beta platelet derived growth factor receptor (β PDGFR)~~, said method comprising the steps of:

a) contacting a sample containing said receptor with

(i) an antibody or fragment thereof which specifically binds α PDGFR ~~or β PDGFR or a fragment thereof~~ wherein the antibody is selected from the group consisting of (a) monoclonal antibody and (b) polyclonal antibody; and

(ii) said test compound;

b) measuring the amount of said antibody or fragment thereof bound to said receptor, said amount being inversely proportional to the amount of test compound which bound to said receptor.

15. (currently amended) The method of claim 14, wherein the test compound is an agonist of α PDGFR activity.

16. (currently amended) The method of claim 14, wherein the test compound is an antagonist of α PDGFR activity.

17. (previously presented) The method of claim 14, wherein the test compound is a PDGF-AA isoform.

18. (previously presented) The method of claim 14, wherein the test compound is a PDGF-AB isoform.

19. (cancelled)

20. (currently amended) The method of claim 14, wherein the antibody or fragment thereof is specific for ~~a protein having the amino acid sequence of~~ a human type α PDGF receptor protein.

21. (cancelled)

22. (new) The method of claim 14, wherein the affinity with which the substance binds to α PDGFR is compared to the affinity with which the PDGF AA isoform binds to α PDGFR.

23. (new) The method of claim 14, wherein the affinity with which the substance binds to α PDGFR is compared to the affinity with which the PDGF AB isoform binds to α PDGFR.

24. (new) The method of claim 14, wherein the antibody or fragment thereof is an antibody that binds to α PDGFR but not to β PDGFR.

25. (new) A method of determining the ability of a substance to bind to Platelet-derived growth factor receptor alpha (α PDGFR) comprising:

a) providing a sample containing cells expressing α PDGFR;

b) exposing said sample of cells expressing α PDGFR to a compound suspected of binding to α PDGFR; and

c) measuring the amount of α PDGFR activity after exposure of the cell sample.

26. (new) The method of claim 25, wherein the compound is an agonist of α PDGFR activity.

27. (new) The method of claim 25, wherein the compound is an antagonist of α PDGFR activity.

28. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the ability of the PDGF AA isoform to bind to α PDGFR.

29. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the ability of the PDGF AB isoform to bind to α PDGFR.

30. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the binding ability of an antibody or fragment thereof that binds to α PDGFR but not to β PDGFR.

31. (new) The method of claim 25, wherein the cells expressing α PDGFR are a cell line containing a recombinant construct expressing α PDGFR.

32. (new) The method of claim 25, wherein the cells expressing α PDGFR are a cell line expressing α PDGFR.